<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-01-20" updated="2019-12-02">
  <drugbank-id primary="true">DB13980</drugbank-id>
  <name>Copper Cu-64</name>
  <description>Copper-64 is a radiopharmaceutical usually found in the +2 oxidation state as the complexes including the +1 state tend to be more unstable.[T604] It is used in molecular radiotherapy and positron emission tomography.</description>
  <cas-number>13981-25-4</cas-number>
  <unii>2MK2L64N0S</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks>
      <textbook>
        <ref-id>T604</ref-id>
        <isbn/>
        <citation>Nairne J., Iveson P. and Meijer A. (2015). Progress in medicinal chemistry (54th ed.). Elsevier.</citation>
      </textbook>
    </textbooks>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002631</drugbank-id>
      <name>Cupric chloride anhydrous Cu-64</name>
      <unii>3IGV2Y2378</unii>
      <cas-number>35121-64-3</cas-number>
      <inchikey>ORTQZVOHEJQUHG-OUMJLSBWSA-L</inchikey>
      <average-mass>134.83</average-mass>
      <monoisotopic-mass>133.8674733</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">Copper, Cu-64</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cuprymina</name>
      <labeller>Sparkle S.R.L</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002136</ema-product-code>
      <ema-ma-number>EU/1/12/784/001</ema-ma-number>
      <started-marketing-on>2012-08-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength>925 MBq/ml</strength>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Dermamed Nutrition for troubled skin</name>
      <labeller>DermaMed</labeller>
      <ndc-id/>
      <ndc-product-code>69711-687</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, gelatin coated</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part347</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Cuprymina</name>
      <ingredients>Copper Cu-64</ingredients>
    </mixture>
    <mixture>
      <name>Dermamed Nutrition for troubled skin</name>
      <ingredients>Ascorbic acid + Copper Cu-64 + Magnesium aspartate + Thiamine + Vitamin A + Vitamin D + Zinc gluconate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form/>
      <route/>
      <strength>925 MBq/ml</strength>
    </dosage>
    <dosage>
      <form>Capsule, gelatin coated</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Copper-64</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>